Evidence map›Paper›PMID 30894686›Full record

ArticleBritish journal of cancer2019

Exome and immune cell score analyses reveal great variation within synchronous primary colorectal cancers.

Ulrika A Hänninen, Erkki-Ville Wirta, Riku Katainen, Tomas Tanskanen, Jiri Hamberg, Minna Taipale, Jan Böhm, Laura Renkonen-Sinisalo, Anna Lepistö, Linda M Forsström and 6 more

Abstract read
In one paragraph

Article in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. 53BP1 expression and immunoscore are associated with the efficacy of neoadjuvant chemoradiotherapy for rectal cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020
    Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ulrika A HänninenApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Erkki-Ville WirtaDepartment of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.
Riku KatainenApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Tomas TanskanenApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Jiri HambergApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Minna TaipaleDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Jan BöhmDepartment of Pathology, Central Finland Central Hospital, Jyväskylä, Finland.
Laura Renkonen-SinisaloDepartment of Surgery, Helsinki University Central Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.
Anna LepistöDepartment of Surgery, Helsinki University Central Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.
Linda M ForsströmApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Esa PitkänenApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Kimmo PalinApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Toni T SeppäläDepartment of Surgery, Helsinki University Central Hospital, Hospital District of Helsinki and Uusimaa, Helsinki, Finland.
Netta MäkinenApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland.
Jukka-Pekka MecklinDepartment of Surgery, Central Finland Central Hospital, Jyväskylä, Finland.
Lauri A AaltonenApplied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland. lauri.aaltonen@helsinki.fi.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundApproximately 4% of colorectal cancer (CRC) patients have at least two simultaneous cancers in the colon. Due to the shared environment, these synchronous CRCs (SCRCs) provide a unique setting to study colorectal carcinogenesis. Understanding whether these tumours are genetically similar or distinct is essential when designing therapeutic approaches.

methodsWe performed exome sequencing of 47 primary cancers and corresponding normal samples from 23 patients. Additionally, we carried out a comprehensive mutational signature analysis to assess whether tumours had undergone similar mutational processes and the first immune cell score analysis (IS) of SCRC to analyse the interplay between immune cell invasion and mutation profile in both lesions of an individual.

resultsThe tumour pairs shared only few mutations, favouring different mutations in known CRC genes and signalling pathways and displayed variation in their signature content. Two tumour pairs had discordant mismatch repair statuses. In majority of the pairs, IS varied between primaries. Differences were not explained by any clinicopathological variable or mutation burden.

conclusionsThe study shows major diversity within SCRCs. Rather than rely on data from one tumour, our study highlights the need to evaluate both tumours of a synchronous pair for optimised targeted therapy.

Indexed as

AgedAged, 80 and overCase-Control StudiesCD3 ComplexCD8 AntigensCD8-Positive T-LymphocytesColorectal NeoplasmsDNA Mutational AnalysisExomeFemaleHumansLymphocytesMaleMicrosatellite InstabilityMiddle AgedMutationCD3 ComplexCD8 Antigens

Identifiers

PMID30894686
PMCPMC6734647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.